Dov Bergwerk, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd., filed a statement of changes in beneficial ownership on November 17, 2026, reporting the vesting of restricted share units and an acquisition of ordinary shares on November 15, 2026.

Key Highlights

  • Reporting person: Dov Bergwerk, identified as Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd.
  • Transaction: 8,370 ordinary shares acquired (transaction code M) on November 15, 2026, through the settlement of restricted share units.
  • Post-transaction ownership: Bergwerk directly holds 20,313 ordinary shares following the reported transaction.
  • RSU grant date: The restricted share units were granted on November 15, 2023, with 8,370 units vesting annually on each of November 15, 2024, November 15, 2025, and November 15, 2026.
  • Remaining RSUs: 8,372 restricted share units remain outstanding and are scheduled to vest on November 15, 2027.
  • Price of derivative security: The price of the restricted share units at settlement is listed as $0.

Bergwerk's RSU Settlement and Resulting Share Position at Teva

According to the filing, Dov Bergwerk, serving as Interim Chief Legal Officer at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), reported the settlement of 8,370 restricted share units on November 15, 2026. The transaction code recorded is M, indicating the conversion of a derivative security into ordinary shares. The filing notes that each restricted share unit "represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company with operations including the development and marketing of generic and specialty medicines. The restricted share units involved in this transaction were part of a grant made on November 15, 2023. Per the filing's explanation of responses, 8,370 units vested on each of November 15, 2024, November 15, 2025, and November 15, 2026, following a structured annual vesting schedule. Following the November 15, 2026 settlement, Bergwerk directly holds 20,313 ordinary shares, the filing states.

In Table II of the filing, 8,372 restricted share units remain beneficially owned by Bergwerk on a direct basis, with vesting scheduled for November 15, 2027. The price of the derivative security is recorded as $0. The filing was signed by Dov Bergwerk and dated November 17, 2026.

What Was Disclosed

The filing reported the vesting and settlement of 8,370 restricted share units into ordinary shares of Teva Pharmaceutical Industries Ltd. by Interim Chief Legal Officer Dov Bergwerk on November 15, 2026, leaving him with 20,313 ordinary shares held directly and 8,372 RSUs outstanding.